Humacyte, Inc. (HUMA)
0.6503
-0.04
(-6.12%)
USD |
NASDAQ |
Aug 28, 16:00
0.6503
0.00 (0.00%)
After-Hours: 20:00
Humacyte Price to Book Value : 5.779 for Aug. 28, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 6.156 |
| August 26, 2026 | 6.057 |
| August 25, 2026 | 6.231 |
| August 24, 2026 | 5.885 |
| August 21, 2026 | 5.707 |
| August 20, 2026 | 6.055 |
| August 19, 2026 | 6.531 |
| August 18, 2026 | 5.169 |
| August 17, 2026 | 4.982 |
| August 14, 2026 | 5.375 |
| August 13, 2026 | 4.888 |
| August 12, 2026 | 5.910 |
| August 11, 2026 | 6.309 |
| August 10, 2026 | 6.616 |
| August 07, 2026 | 6.382 |
| August 06, 2026 | 6.306 |
| August 05, 2026 | 6.476 |
| August 04, 2026 | 6.329 |
| August 03, 2026 | 6.126 |
| July 31, 2026 | 5.806 |
| July 30, 2026 | 5.968 |
| July 29, 2026 | 5.550 |
| July 28, 2026 | 5.605 |
| July 27, 2026 | 5.990 |
| July 24, 2026 | 5.552 |
| Date | Value |
|---|---|
| July 23, 2026 | 5.675 |
| July 22, 2026 | 5.728 |
| July 21, 2026 | 5.961 |
| July 20, 2026 | 5.831 |
| July 17, 2026 | 5.907 |
| July 16, 2026 | 5.862 |
| July 15, 2026 | 6.057 |
| July 14, 2026 | 6.285 |
| July 13, 2026 | 6.142 |
| July 10, 2026 | 6.165 |
| July 09, 2026 | 6.223 |
| July 08, 2026 | 6.516 |
| July 07, 2026 | 6.851 |
| July 06, 2026 | 6.848 |
| July 02, 2026 | 6.309 |
| July 01, 2026 | 5.977 |
| June 30, 2026 | 6.935 |
| June 29, 2026 | 15.26 |
| June 26, 2026 | 13.53 |
| June 25, 2026 | 11.84 |
| June 24, 2026 | 13.33 |
| June 23, 2026 | 13.38 |
| June 22, 2026 | 16.03 |
| June 18, 2026 | 17.65 |
| June 17, 2026 | 18.50 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amgen, Inc. | 20.00 |
| Altimmune, Inc. | 1.282 |
| Protalix Biotherapeutics, Inc. | 2.866 |
| Taysha Gene Therapies, Inc. | 4.847 |
| Agenus, Inc. | -- |
Price to Book Value Related Metrics
| PS Ratio | 59.57 |
| PEG Ratio | -0.1832 |
| Price | 0.6503 |
| Earnings Yield | -75.29% |
| Market Cap | 180.65M |
| PEGY Ratio | -0.1832 |